The present invention is directed toward the use of the drug Troglitazone and related thiazolidinedione compounds in the treatment of the climacteric and cancer. This use is based on the novel discovery that Troglitazone inhibits steroidogenesis in granulosa cell cultures. This activity is believed to result from the ability of thiazolidinedione derivatives to act as a ligand for the orphan steroid receptor peroxisome proliferator-activated receptor gamma (PPARgamma). Troglitazone and related co...

A pharmaceutical composition comprises a Parkinson's disease treating effective amount of a combination of a forebrain selective NMDA antagonist and an excitatory feedback enhancing agent with a pharmaceutically acceptable diluent or carrier and optionally carbidopa. The forebrain selective NMDA antagonist can be (+)-(1S,2S)-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol, (1S,2S)-1-(4-hydroxy-3-methoxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol and (3R,4S)-3-(4-(4-fluor...